Moroishi, Yuka
Gui, Jiang
Nadeau, Kari C.
Morrison, Hilary G.
Madan, Juliette
Karagas, Margaret R.
Article History
Received: 24 March 2022
Revised: 23 May 2022
Accepted: 26 May 2022
First Online: 18 June 2022
Competing interests
: K.C.N. reports grants from National Institute of Allergy and Infectious Diseases (NIAID), National Heart, Lung, and Blood Institute (NHLBI), National Institute of Environmental Health Sciences (NIEHS), and Food Allergy Research & Education (FARE); stock options from IgGenix, Seed Health, ClostraBio, and ImmuneID; is Director of World Allergy Organization (WAO), Advisor at Cour Pharma, Consultant for Excellergy, Red tree ventures, Eli Lilly, and Phylaxis, Co-founder of Before Brands, Alladapt, Latitude, and IgGenix; and National Scientific Committee member at Immune Tolerance Network (ITN), and National Institutes of Health (NIH) clinical research centers, outside the submitted work; patents include “Mixed allergen composition and methods for using the same,” “Granulocyte-based methods for detecting and monitoring immune system disorders,” “Methods and assays for detecting and quantifying pure subpopulations of white blood cells in immune system disorders,” and “Methods of isolating allergen-specific antibodies from humans and uses thereof.” All other authors declare no conflicts of interest.
: The Committee for the Protection of Human Subjects at Dartmouth College approved all protocols, and we provided written informed consent to all participants upon enrollment to this study.